New combo aims to boost survival in aggressive lung cancer
NCT ID NCT07055581
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial is testing whether adding the immunotherapy drug durvalumab to standard chemotherapy and radiation can help people with limited-stage small-cell lung cancer live longer without their cancer returning. About 100 participants will receive durvalumab plus chemo before radiation, then durvalumab alone for up to two years. The study is currently recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Durvalumab (an immunotherapy drug) combined with chemotherapy (etoposide and cisplatin or carboplatin) and radiation therapy
- What this could lead to
- If successful, this could offer a new treatment option that improves how long people with limited-stage small-cell lung cancer live without their cancer getting worse.
- What could go wrong
- This is an early phase II study with only 100 participants and no comparison group, so results are uncertain. Immunotherapy can cause immune-related side effects like lung inflammation or colitis.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER LIMITED STAGE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital
RECRUITINGZhengzhou, Henan, 450008, China
-
Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, 430030, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.